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Background: Continuous surveillance for intussusception (IS) is important for monitoring the safety of second-
generation rotavirus vaccines. The present study aimed to assess the incidence of IS in Singaporean children
aged < 2 years.
Methods: This was a prospective, hospital-based, multi-center surveillance conducted in seven hospitals - two
public hospitals and five private medical centers between May 2002 and June 2010 in Singapore. Diagnosis of IS
(definite, probable, possible, suspected) was based on the case definition developed by the Brighton Collaboration.
Children < 2 years of age who were diagnosed with IS were enrolled in this study. Incidence of IS was calculated
per 100,000 child-year with its 95% confidence interval.
Results: Of the 178 children enrolled, 167 children with definite IS cases were considered for final analyses; 11 were
excluded (six diagnosed as probable IS and four diagnosed as suspected IS; one child’s parents withdrew consent).
Mean age of children with definite IS was 11.6 ± 6 months; 67.7% were males. The overall incidence of IS was 28.9
(95% CI: 23.0–34.8) and 26.1 (95% CI: 22.2–30.0) per 100,000 child-year in children < 1 year and < 2 years of age,
respectively. The majority of IS cases (20 [12.0%]) were reported in children aged 6 months. Most children (98.2%
[164/167]) recovered, two (1.2%) children recovered with sequelae and one (0.6%) child died of septic shock.
Conclusions: The incidence of IS remained low and stable in Singaporean children aged < 2 years during the
study period (May 2002 to June 2010).
Trial registration: NCT01177839
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Intussusception (IS) is one of the most frequent causes
of abdominal surgical emergencies in young children [1].
It occurs when one segment of bowel invaginates into the
distal bowel, resulting in venous congestion and bowel
wall edema [2]. Early diagnosis of IS is done using ultra-
sonography and/or air/hydrostatic enema. Air/hydrostatic
enema is also used for the treatment of IS, in addition to
surgical reduction of IS [3]. IS cases are most commonly
observed in young children within the first year of life and
are rare in children aged < 6 weeks, older children and* Correspondence: Phua.Kong.Boo@kkh.com.sg
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reproduction in any medium, provided the oradults [2]. The causes of IS are unknown in most cases.
However, the frequent association of IS with intestinal
lymphoid hyperplasia suggests that infectious agents may
play a role [1].
Rotaviruses are the most important cause of severe diar-
rhea in young children accounting for over 453,000 deaths
annually, worldwide [4]. In a study by Robinson CG, et al.,
it was demonstrated that rotavirus infection resulted in the
thickening of distal ileal wall and mesenteric lymphaden-
opathy, suggesting a plausible mechanism of rotavirus-
induced IS [5]. However, previous reports indicate no
association between IS and rotavirus infection [6-8].
A first generation rotavirus vaccine, RotashieldW
(Rotashield, Wyeth, Philadelphia, PA, USA), was withdrawnd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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post-licensure surveillance revealed that administration of
RotashieldW was temporally associated with an increased
risk of IS and hence was withdrawn from the market by the
manufacturer [9,10]. This incident has a considerable im-
pact on the development and usage of next generation rota-
virus vaccines [11,12].
Live attenuated oral rotavirus vaccines namely Rotarix™
(RIX4414, GlaxoSmithKline, Belgium) was licensed in
Singapore in November 2005 and RotaTeqW (RV5, Merck
and Co., Inc., USA) was licensed in Singapore in July 2007
[13]. These vaccines did not demonstrate any association
with IS in large-scale, pre-licensure clinical trials [14,15].
Post marketing surveillance conducted in Mexico [16] and
Australia [17] revealed an increased risk of IS following
the administration of first dose of both these vaccines.
However, recent studies have indicated that the benefits of
rotavirus vaccines outweigh the risks [18,19]. To assess the
risk-benefit ratio of the rotavirus vaccines in Singapore, it
is, therefore, essential to collect the baseline information
on the incidence of IS.
This study aimed to determine the incidence of IS in
Singaporean children aged < 2 years through a prospec-
tive hospital-based surveillance conducted between 2002
and 2010.Methods
Study design and study population
This prospective, hospital-based, multi-centre surveillance
study was conducted in two public (KK Women's and
Children's Hospital, the National University Hospital) and
five private hospitals (Mount Elizabeth Hospital, Gleneagles
Hospital, Mount Alvenia Hospital, East Shore Hospital,
Thomson Medical Centre) in Singapore between May 2002
and July 2010. These hospitals treated the majority of IS
cases in Singapore. The KK Women’s and Children’s
Hospital alone treated nearly 72% of IS cases in Singapore
[20]. Since all children with IS cases in Singapore were
admitted to hospitals, this study covered almost all repor-
ted IS cases.
All children aged < 2 years and admitted to the study
hospitals with a diagnosis of IS–categorized as definite
(ascertained by: radiograph, surgery or by post-mortem
examination), probable, possible or suspected cases
based on the criteria developed by the Brighton Collabo-
ration Working Group (version dated January 30, 2002)
[21], were enrolled.
Data on IS were obtained from the daily admission
logs, computerized hospital admission records, emer-
gency department records, surgical records and radi-
ology logs that were reviewed by the study staff and also
from the discharge case notes that were written by sur-
geon to confirm the IS case. These were then keyed intothe hospital database under the International Classifica-
tion of Diseases (ICD) code for IS. In addition, the emer-
gency department pediatric surgeons at each study site
were involved to ensure that all IS cases were captured.
All departments that were responsible for the manage-
ment of IS cases were advised to contact the study
personnel for each case of IS to ensure that all cases
were captured. Each site gave an outline of their
methods of surveillance, and provided evidence that case
finding and ascertainment was sufficiently sensitive.
Clinical signs and symptoms of IS and vaccination
history at the time of admission to hospitals were recor-
ded in the case report forms. Children were excluded from
the study if their age at the time of enrollment was ≥ 2 years
or if the children had an episode of definite IS confirmed
radiographically or surgically before enrollment.
Written informed consent forms were collected from
children’s parents/ guardians prior to enrollment. This
study was approved by the Institutional Review Board
of each study centre in Singapore: KK Women’s and
Children’s Hospital IRB/EC (KK Women’s and Children’s
Hospital), National Healthcare Group HQ Domain Specific
Review Board (DSRB) (National University Hospital) and
Parkway Independent Ethics Committee (Mt. Elizabeth
Hospital, Gleneagles Hospital, East Shore Hospital,
Thomson Medical Centre and Mt. Alvenia Hospital).
The study was conducted as per the principles of
Good Clinical Practice, International Guidelines for
Ethical Review of Epidemiological Studies, local regu-
lations in Singapore and the Declaration of Helsinki.
Diagnostic procedures
Abdominal radiograph, abdominal ultrasound, abdom-
inal computed tomography (CT), gas/ liquid contrast
enema and surgery were used to diagnose IS. The
number of children who underwent each of these
diagnostic procedures was recorded. The outcome of
hospital admission was collected.
Microbiology
Available stool samples were collected from subjects with
definite IS as a part of routine diagnostic procedure.
Microbiological examination of these stool samples was
performed to determine the presence of any microbial
(bacteria such as Escherichia coli, Campylobacter, Salmon-
ella, Yersinia and Shigella) and/or viral (namely rotavirus)
pathogens. Microbial detection was done using stool cul-
ture and rotavirus was detected using commercial test kits
(antigen detection, latex agglutination and immunochro-
matographic tests).
Statistical analyses
The incidence of IS was calculated using the following
formula:
Annual Incidence of IS ¼ Number of new IS cases reported in a specific year
The total number of children living in Singapore during the specific year
 100; 000
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living in Singapore during the specific year.
The incidence of IS among children aged < 1 year
and < 2 years were calculated with their respective
exact 95% confidence intervals (95% CI). Incidence of
IS was expressed per 100,000 child-year.
The trend in incidence of IS hospitalizations from May
2002 to July 2010 was assessed. Further, seasonal varia-
tion in the occurrence of IS by month was also assessed
for the entire study period.Results
Demography
A total of 178 children were assessed for IS of which six
were probable, four were suspected IS cases. The remai-
ning 168 children were definite IS cases. Of these, one
child’s parent withdrew consent after enrolment. A total
of 167 children were thus enrolled and included in the
final analyses.
The mean age of children included in the final analyses
was 11.62 ± 6.22 months; 67.7% of enrolled children were































































Figure 1 Clinical symptoms observed in children with definite IS casereceived RIX4414 and RV5, respectively. Following the ad-
ministration of RIX4414, IS case was reported by 2/17
children seven days post-Dose 1 and 1/17 child between
7–31 days post-Dose 2. Children receiving RV5 did not
report IS cases within 31 days following any dose.
Vomiting (144/167 [86.7%]), lethargy (78/167 [65%])
and abdominal mass (60/167 [38%]) were the most
commonly reported clinical symptoms among children
hospitalized with definite IS cases (Figure 1).Incidence
The overall incidence of IS observed in children aged < 1 year
and < 2 years was 28.9 (95% CI: 23.0–34.8) and 26.1
(95% CI: 22.2–30.0) per 100,000 child-year, respect-
ively. The annual incidence of IS during the entire
study period is detailed in Table 1. The highest num-
ber of IS cases (20/167 [12.0%]) were reported in the
age group of six months (Figure 2). The number of
IS cases during the entire study period did not show
any clear seasonal pattern (data not shown). The
number of IS cases were predominantly higher in




















































































Total number of Cases: N=167
(Total number of cases N=167).
Table 1 Incidence of IS among children < 1 and < 2 years
of age (N=167)






LL UL LL UL
2002* 44.5 19.3 69.7 31.5 16.6 46.5
2003 32.1 13.9 50.3 29.4 17.1 41.7
2004 35.0 16.0 54.0 43.0 28.1 57.9
2005 37.4 17.8 57.1 25.4 14.0 36.8
2006 28.8 11.8 45.8 24.9 13.7 36.1
2007 33.0 15.1 51.0 25.4 14.3 36.5
2008 27.6 11.3 43.9 31.4 19.1 43.7
2009 7.6 0.0 16.2 10.1 3.1 17.2
2010** 15.3 0.3 30.3 11.5 2.3 20.7
95% CI: exact 95% confidence interval; LL: lower limit; UL: upper limit.
Children < 2 years include children < 1 year and children aged 1–2 years.
*Data collected from May to December - 2002.
**Data collected from January to June - 2010.
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The majority of children (166/167 [99.4%]) underwent ab-
dominal ultrasound; abdominal radiograph was performed
on 96/167 (57.5%) children and gas/ liquid contrast enema
was performed on 95/167 (56.9%) children. Furthermore,
33/167 (19.8%) children underwent surgery and bowel re-
section was performed in 18/167 (10.8%) children.Outcomes
Of the 167 children hospitalized with definite IS, 164


















Figure 2 Distribution of IS cases by age (Total number of cases N=16who underwent surgery recovered with sequelae and
one child died of septic shock.
One child who recovered with sequele had a successful
reduction of IS by surgery but developed E. coli septicae-
mia and acute tubular necrosis which required dialysis.
One child developed pneumoperitoneum following air
enema. This child underwent laparotomy and hemico-
lectomy was carried out because of serosal split. How-
ever, this child recovered fully. The child who died
during the study period had undergone air reduction
and had recovered from IS. Despite having fully reco-
vered from the IS episode, the child died a month later.
Autopsy revealed necrotising enterocolitis, severe hya-
line membrane disease, severe generalized lymphocytic
depletion and haemosidrosis of the liver and spleen.
Microbiology
A total of 53 (31.7%) stool samples were available from
167 children for microbiological analyses. Microbial
examination revealed that three distinct samples were
positive for Salmonella while Escherichia coli and Cam-
pylobacter were found in one distinct sample each.
There were no mixed infections. Rotavirus was not
isolated from any of the samples tested.
Discussion
This prospective hospital-based surveillance spanning a
period of eight years was the largest study aimed at pro-
viding recent estimates of IS incidence in Singapore.
During the eight year surveillance period, the observed
incidence of IS was low with an overall incidence
estimated at 28.9 and 26.1 per 100,000 child-year in
children < 1 and < 2 years of age, respectively. This is in(months)






















2002* 2003 2004 2005 2006 2007 2008 2009 2010**
Figure 3 Distribution of IS cases by gender (Total number of cases N=167). *Data collected from May to December - 2002. **Data collected
from January to June - 2010.
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Singapore, where the incidence ranged between 26.4
and 39.9 per 100,000 among children aged < 1 year and
between 23.8 and 28.7 per 100,000 among children
aged < 2 years, during 2005–2007 [13]. The IS incidence
values observed in Singapore in the present study and
the one conducted previously were lower than that ob-
served in Taiwan (77.0 and 93.5 per 100,000 child-year
in children < 1 and < 2 years of age, respectively) [22]
and Germany (60.4 and 51.5 per 100,000 child-year in
children < 1 and < 2 years of age, respectively) [23].
Although the exact reason for this low IS incidence is
unknown, a study conducted by Tan N et al., [13] indi-
cated that the baseline incidence of IS was lower in
Singapore.
Furthermore, the present results indicate that during
the eight year surveillance, the incidence of IS was
lowest in 2009. Although the exact reason for the lower
IS incidence rate observed in 2009 in the present study
is unknown, natural fluctuation of IS cases might have
caused this effect.
The present study demonstrated a higher incidence of
IS in children aged < 1 year as compared to children
aged < 2 years which is in accordance with a previously
conducted study in Singapore [13]. A review of pub-
lished literature between 1966 and 2001 by the World
Health Organization on the worldwide IS incidence also
showed that the incidence of IS was higher in children
aged < 1 year than in children aged < 2 years [2]. Fur-
thermore, the peak incidence of IS was observed
between 4–8 months of age, with highest number of
cases reported at six months of age. These results werealso similar to the results observed in other studies
conducted in Taiwan [22], Korea [24], Thailand [25],
Australia [26] and also the United States where two-
thirds of IS cases occur below the age of one year [27].
While the peak incidence of IS was observed at six
months of age, a secondary peak was observed at
18 months of age, which was similar to previous findings
in Taiwan and Australia [22,26]. However the exact
reason for this peak in the incidence of IS at 18 months
is not known.
Of the 53 available stool samples collected from
definite cases of IS, none of the samples tested posi-
tive for rotavirus. These results indicate that, among the
children with definite IS and from whom stool samples
were collected, the cause of IS can be assumed to be
non-rotavirus related.
There were several limitations which might affect the
interpretation of results observed in this present study.
The information regarding the application of different
diagnostic procedures stepwise was not captured in this
study. Therefore, it was not possible to determine the
number of IS cases confirmed by a single diagnostic pro-
cedure. Since there was no distinction between diagnostic
and therapeutic procedures, it was not possible to classify
the therapeutic procedures explicitly. For instance, chil-
dren who underwent surgery might have had another
treatment measure prior to surgery and surgery was
opted for only when the other treatment measures were
unsuccessful. These limitations might have led to potential
bias in reporting the diagnostic/ treatment procedures
in Singapore. Lastly, stool samples were not actively
collected as part of this study. Microbial examination was
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children during routine clinical examination and analyzed.
Furthermore, the microbial examination did not include
specific tests for the detection of non-enteric viruses such
as adenovirus.
Conclusions
This study provides the baseline information on the inci-
dence of IS which might aid in assessing the risk-benefit
ratio of rotavirus vaccines in Singapore.
Incidence of IS remained stable and low during the
eight year surveillance period from May 2002 to June
2010 in Singaporean children aged < 2 years. Children
aged < 1 year were more frequently affected with IS than
children < 2 years of age. The therapeutic procedures
carried out at the study hospitals demonstrated success-
ful reduction of IS in majority of children.
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